SCHEMBL23218364

SCHEMBL23218364

CCOC(=O)c1coc2c(OCCC3CCOCC3)cc(Br)cc12

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.42
PIM2 Q9P1W9 1/20 0.42
PDE4B Q07343 8/20 0.37
RXFP1 Q9HBX9 2/20 0.36
CNR2 P34972 3/20 0.35
CNR1 P21554 1/20 0.35
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAPT P10636 1/20 0.34
USP2 O75604 1/20 0.33
TP53 P04637 1/20 0.33
MAPK1 P28482 1/20 0.33
RECQL P46063 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852968 1.00 PIM1 (0.42) PIM1PIM2PDE4BRXFP1CNR2
SCHEMBL28736178 0.89 PIM1 (0.38) PIM1PIM2PDE4BRXFP1CNR2
SCHEMBL29852520 0.83 PIM1 (0.44) PIM1PIM2CNR2ALDH1A1SMN1; SMN2
SCHEMBL23218202 0.83 PIM1 (0.44) PIM1PIM2CNR2ALDH1A1SMN1; SMN2
SCHEMBL29852772 0.82 RXFP1 (0.50) RXFP1ALDH1A1MAPTMAPK1HSD17B10
SCHEMBL23219059 0.82 RXFP1 (0.50) RXFP1ALDH1A1MAPTMAPK1HSD17B10
SCHEMBL23218621 0.81 ALDH1A1 (0.39) RXFP1ALDH1A1SMN1; SMN2MAPTMAPK1
SCHEMBL29853126 0.81 ALDH1A1 (0.39) RXFP1ALDH1A1SMN1; SMN2MAPTMAPK1
SCHEMBL23218776 0.79 PIM1 (0.41) PIM1PIM2CNR2CNR1
SCHEMBL29592656 0.79 PIM1 (0.41) PIM1PIM2CNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB PIM1 4538/4885PIM2 4286/4885PDE4B 4512/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB PIM1 4497/4885PIM2 4673/4885PDE4B 3248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.